Pathnostics to Present New Real-World Method to Identify and Evaluate Cost Outcomes of a Novel, Uncoded UTI Diagnostic at the International Society for Pharmacoeconomics and Outcomes Research 2022 Annual Meeting
IRVINE, Calif., May 16, 2022 /PRNewswire/ -- Pathnostics, a leading precision diagnostic testing and development company, today announced that it will present a new Medicare-claims-based method to identify an uncoded novel diagnostic (NDx), Guidance® UTI, and an analysis that found significantly lower costs as compared to standard urine culture (SUC) in patients with complicated urinary tract infections (cUTIs). The methodology and key findings will be presented at the 2022 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, taking place from May 15-18, in National Harbor, MD.
- The methodology and key findings will be presented at the 2022 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, taking place from May 15-18, in National Harbor, MD.
- Complicated urinary tract infections, which must be treated early and accurately to reduce the risk of poor outcomes, are a significant burden on individual health and healthcare resources.
- Annually, UTIs contribute to 10.5 million office visits and carry a cost of approximately $3.5 billioni.
- Details of the poster presentation are as follows:
The abstract and poster are now available on the ISPOR 2022 Conference website.